Clinical journal of the American Society of Nephrology : CJASN · 2025
GLP-1 Receptor Agonist Outcomes, Safety, and Body Mass Index Change in a National Cohort of Patients on Dialysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Orandi Babak J, Chen Yusi, Li Yiting, Charytan David, Lentine Krista L, Lee Brian P, Ali Nicole, DeMarco Mario P, Weintraub Michael A, Bae Sunjae, Lonze Bonnie E, Ren-Fielding Christine J, Lofton Holly, Gujral Akash, Segev Dorry L, McAdams-DeMarco Mara
Аннотация
KEY POINTS: GLP-1 receptor agonists (GLP-1 RAs) in diabetes and dialysis are associated with 23% lower mortality and 66% higher chance of transplant waitlisting. GLP-1 RAs are not associated with increased risk of acute pancreatitis, biliary complications, or medullary thyroid cancer. GLP-1 RAs are associated with a 32% increased risk of diabetic retinopathy in patients with diabetes on dialysis.
BACKGROUND: Of the 808,000 US patients on dialysis, 60% have diabetes and are eligible for glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Safety and outcomes in this population are unknown. We sought to examine GLP-1 RA real-world safety, efficacy, and weight loss in people with diabetes on dialysis.
METHODS: In this observational national cohort study (2013–2021), we identified adults with type 2 diabetes on dialysis. The exposure of interest was GLP-1 RA use. Body mass index (BMI) change after dialysis initiation was quantified among patients with two measurements (N=6474). Extended Cox models with inverse probability of treatment weights (censoring for kidney transplant waitlisting) were used to quantify all-cause mortality associated with GLP-1 RAs. Specific safety outcomes (acute pancreatitis, biliary complications, medullary thyroid cancer, and diabetic retinopathy) were assessed.
RESULTS: The study included 151,649 patients on incident dialysis with type 2 diabetes. Mean BMI and weight change among GLP-1 RA users were greater than those among nonusers (−1.47 versus −0.61 kg/m2; −4.03 versus −1.47 kg; P < 0.001 for both). The mortality incidence rate was lower among GLP-1 RA users (219.0 versus 279.5 patients/1000 person-years; P < 0.001). GLP-1 RA use was associated with a 23% lower risk of mortality (adjusted hazard ratio [aHR], 0.77; 95% confidence interval [CI], 0.70 to 0.85; P < 0.001); results were consistent among initiates with BMI ≥30 kg/m2. GLP-1 RA use was associated with a 66% higher chance of waitlisting (aHR, 1.66; 95% CI, 1.28 to 2.13; P < 0.001). There was an increased association with diabetic retinopathy (aHR, 1.32; 95% CI, 1.12 to 1.56; P = 0.001), but not with any other safety outcomes. Inferences were consistent across multiple sensitivity analyses.
CONCLUSIONS: GLP-1 RA use in patients with type 2 diabetes on dialysis was associated with weight loss, reduced mortality risk, and increased likelihood of kidney transplant waitlisting. These real-world data are the strongest evidence to date supporting GLP-1 RA use in this population.
BACKGROUND: Of the 808,000 US patients on dialysis, 60% have diabetes and are eligible for glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Safety and outcomes in this population are unknown. We sought to examine GLP-1 RA real-world safety, efficacy, and weight loss in people with diabetes on dialysis.
METHODS: In this observational national cohort study (2013–2021), we identified adults with type 2 diabetes on dialysis. The exposure of interest was GLP-1 RA use. Body mass index (BMI) change after dialysis initiation was quantified among patients with two measurements (N=6474). Extended Cox models with inverse probability of treatment weights (censoring for kidney transplant waitlisting) were used to quantify all-cause mortality associated with GLP-1 RAs. Specific safety outcomes (acute pancreatitis, biliary complications, medullary thyroid cancer, and diabetic retinopathy) were assessed.
RESULTS: The study included 151,649 patients on incident dialysis with type 2 diabetes. Mean BMI and weight change among GLP-1 RA users were greater than those among nonusers (−1.47 versus −0.61 kg/m2; −4.03 versus −1.47 kg; P < 0.001 for both). The mortality incidence rate was lower among GLP-1 RA users (219.0 versus 279.5 patients/1000 person-years; P < 0.001). GLP-1 RA use was associated with a 23% lower risk of mortality (adjusted hazard ratio [aHR], 0.77; 95% confidence interval [CI], 0.70 to 0.85; P < 0.001); results were consistent among initiates with BMI ≥30 kg/m2. GLP-1 RA use was associated with a 66% higher chance of waitlisting (aHR, 1.66; 95% CI, 1.28 to 2.13; P < 0.001). There was an increased association with diabetic retinopathy (aHR, 1.32; 95% CI, 1.12 to 1.56; P = 0.001), but not with any other safety outcomes. Inferences were consistent across multiple sensitivity analyses.
CONCLUSIONS: GLP-1 RA use in patients with type 2 diabetes on dialysis was associated with weight loss, reduced mortality risk, and increased likelihood of kidney transplant waitlisting. These real-world data are the strongest evidence to date supporting GLP-1 RA use in this population.